| NCT05706038 |
Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse |
NULL |
COMPLETED |
IRCCS San Raffaele |
Inflammatory Bowel Diseases|Rheumatic Disorder |
DRUG: Adalimumab |
Details |
| NCT05688852 |
VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease |
PHASE2 |
TERMINATED |
Ventyx Biosciences, Inc |
Crohn Disease |
DRUG: VTX958|DRUG: VTX958|DRUG: VTX958 Placebo |
Details |
| NCT05687474 |
Baby Detect : Genomic Newborn Screening |
NULL |
COMPLETED |
Centre Hospitalier Universitaire de Liege |
Congenital Adrenal Hyperplasia|Familial Hyperinsu… |
None |
Details |
| NCT05686135 |
90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients |
NA |
WITHDRAWN |
Jennifer Jones |
IBD|Crohn Disease|Ulcerative Colitis |
OTHER: 90Second IBD |
Details |
| NCT05668104 |
Jing Si Herbal Tea for Long-Coronavirus Disease(COVID) Gut-brain Interaction |
NA |
COMPLETED |
Buddhist Tzu Chi General Hospital |
Healthy Subjects|COVID-19 Pneumonia|Irritable Bow… |
DIETARY_SUPPLEMENT: Jing Si Herbal Tea Liquid Pac… |
Details |
| NCT05584735 |
Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine |
NULL |
COMPLETED |
University of Wisconsin, Madison |
Inflammatory Bowel Diseases |
BIOLOGICAL: Influenza vaccine|BIOLOGICAL: COVID-1… |
Details |
| NCT05549323 |
A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis |
PHASE1 |
TERMINATED |
Pfizer |
Ulcerative Colitis |
DRUG: PF-07054894|DRUG: Placebo |
Details |
| NCT05452304 |
AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease |
PHASE1 |
COMPLETED |
AstraZeneca |
Healthy Subjects|Crohns Disease |
BIOLOGICAL: AZD7798|BIOLOGICAL: Placebo |
Details |
| NCT05389709 |
A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting |
NULL |
COMPLETED |
Bayer |
Functional Gastrointestinal Disorders Such as Irr… |
DRUG: Iberogast (STW5-II, BAY98-7410) |
Details |
| NCT07149441 |
Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study |
NA |
ACTIVE_NOT_RECRUITING |
Shanghai 10th People's Hospital |
Inflammatory Bowel Disease (Crohn&Amp;#39;s Disea… |
PROCEDURE: Fecal microbiota transplantation|DRUG:… |
Details |
| NCT07132333 |
Molecular Inflammation Board at the Center for Personalized Medicine |
NULL |
RECRUITING |
University Hospital Tuebingen |
Psoriasis (PsO)|Psoriasis Arthritis|Inflammatory … |
BIOLOGICAL: Biologic Agent |
Details |
| NCT05242484 |
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis |
PHASE2 |
ACTIVE_NOT_RECRUITING |
Janssen Research & Development, LLC |
Colitis, Ulcerative |
BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… |
Details |
| NCT05242471 |
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease |
PHASE2 |
ACTIVE_NOT_RECRUITING |
Janssen Research & Development, LLC |
Crohn's Disease |
BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… |
Details |
| NCT05240521 |
Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C |
NA |
UNKNOWN |
Devintec Sagl |
Irritable Bowel Syndrome With Constipation (IBS-C) |
OTHER: ARM A|OTHER: ARM B |
Details |
| NCT07125625 |
Probiotic Mixture (L. Rhamnosus GG and L. Plantarum 299V) In Pediatric Irritable Bowel Syndrome |
NA |
NOT_YET_RECRUITING |
University of Bari |
Irritable Bowel Syndrome (IBS) |
DIETARY_SUPPLEMENT: Experimental arm: probiotic|D… |
Details |
| NCT07123350 |
Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease |
NULL |
ACTIVE_NOT_RECRUITING |
Vanderbilt University Medical Center |
Inflammatory Bowel Disease (IBD)|Crohn&Amp;#39;s … |
DRUG: Patient switched from IV vedolizumab to sub… |
Details |
| NCT05153850 |
Assessment of the Response to the Complete Vaccination Guidelines Against Sars-cov2 |
NULL |
UNKNOWN |
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
COVID-19 |
None |
Details |
| NCT05115370 |
Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19 |
NULL |
COMPLETED |
University of Nottingham |
Inflammatory Disease|Rheumatoid Arthritis|Psoriat… |
OTHER: Semi-structured qualitative interview |
Details |
| NCT07421011 |
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers. |
PHASE1 |
RECRUITING |
Valenta Pharm JSC |
Irritable Bowel Syndrome|Gallstone Disease|GERD|B… |
DRUG: Trimedat® |
Details |
| NCT05098600 |
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic |
NULL |
COMPLETED |
Faculty Hospital Kralovske Vinohrady |
Alopecia Areata|Alopecia Totalis|Alopecia Univers… |
OTHER: Exposure of interest |
Details |
